65,437 trials
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Percentage of Participants With Complete Response and Partial Response (Objective Response Rate) — 7.5; 0; 3.1 percentage of participants
Coronary Artery Disease
Primary: Change in Serum Thromboxane B2 — 5.02; 2.78 ng/mL — p=0.005
Peripheral Arterial Disease
Primary: Effectiveness Endpoint Defined as Number of Participants withTarget Lesion Patency by Duplex Ultrasound Defined as Freedom From ≥50% Restenosis — 30 Participants
Uterine Cervical Neoplasms
Primary: Sensitivity of the BD Onclarity™ HPV Assay for the Detection Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN)2 or Greater — 85.7; 44.4 percentage…
Influenza
Primary: Total All-cause Hospitalizations — 197; 301 events
Ductal Carcinoma in Situ - Category · Breast Cancer · Prophylactic Mastectomy
Primary: Percentage of Original Preoperative Blood Supply (Perfusion) Post Nipple Sparing Mastectomy — 63.9; 60.8; 29.9; 40.0 percentage of original preop perfusion
Psoriasis
Primary: The Percentage of Subjects With HPA Axis Suppression. — 36.4; 12.5 percentage of participants — p=0.086
Papillary Thyroid Cancer · Follicular Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Progression Free Survival — 241 days
Asthma
Primary: Adolescent Research Participant Assessment Score at Screening (Visit 1, Week -8) — 41.08; 42.26 Scores on a scale
Parkinson Disease
Primary: Change of Cerebral Glutathione Levels as Measured by Proton Magnetic Resonance Spectroscopy — 3.422; 3.334; 3.745; 4.282 Ratio
HBV · Chronic HBV Infection
Primary: Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 — 89.4; 98.0 percentage of participants
Carcinoma · Neuroendocrine Tumors
Primary: Percentage of Participants With Progression-Free Survival (PFS) Rate at Six Months — 45.2; 41.7; 54.1; 61.4 percentage of participants
Cataracts
Primary: Cumulative Dissipated Energy (CDE) — 6.2; 11.4 percent-seconds — p=<.001
Chronic Obstructive Pulmonary Disease COPD
Primary: Time to First Moderate to Severe COPD Exacerbation or Early Drop-out Related to Worsening of COPD Symptoms — NA; 118.0 days — p=0.2371
Actinic Keratosis
Primary: CC Rate of AK Lesions in the Selected Treatment Area — 49; 8; 15; 1 Participants